Trade Ideas July 11, 2026 04:58 AM

Intel's Turnaround Is Gaining Real Traction — Upgrade to Long

Factory investments, AI-friendly roadmaps and stabilizing margins make $INTC a tactical buy into the next leg of the recovery

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
INTC

Intel's operational recovery is moving from blueprint to execution. Market-cap of $551.9B, rising AI exposure in Data Center & AI (DCAI), and ongoing foundry wins are combining with a compressing valuation gap versus peers. We upgrade to a long trade: entry $109.81, stop $98.00, target $140.00 with a mid-term horizon (45 trading days) for the primary leg and a 180-day view for the larger thesis.

Intel's Turnaround Is Gaining Real Traction — Upgrade to Long
INTC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Upgrade to long: Intel’s execution is shifting from plan to measurable progress in AI and foundry initiatives.
  • Entry $109.81, stop $98.00, target $140.00; mid-term primary horizon (45 trading days), longer-term thesis over 180 days.
  • Valuation reflects high expectations: market cap $551.9B, EV $579.84B, EV/EBITDA 43.85, P/S 10.27 — upside depends on DCAI and IFS execution.
  • Negative free cash flow (-$4.446B) and EPS -$0.63 are near-term realities; catalysts and margin improvement will determine re-rating.

Hook / Thesis

Intel has made the messy part of a turnaround public and measurable: capital allocation, process roadmap stabilization and higher-margin product ramps. Those changes are no longer theoretical. They are showing up in AI-oriented revenue mix gains and improved sentiment on foundry negotiations. The market is starting to price this in, but there is still room for multiple re-ratings as execution continues.

That’s why we are upgrading Intel to a buy trade. At the current price of $109.81 the company is a tactical long: the near-term technical picture is choppy, but the fundamental setup - a diversified product portfolio (Client Computing Group, Data Center & AI, Intel Foundry Services) plus a renewed focus on margin recovery - supports a mid-term move back toward prior highs. Enter at $109.81, stop at $98.00, target $140.00.

What Intel Does and Why the Market Should Care

Intel designs and manufactures processors, networking and storage platforms, and provides foundry services. Its business is organized into four segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS) and All Other. The DCAI segment is the most important for investors today: it sells silicon to cloud providers, enterprises, and high-performance computing customers and is the prime conduit for AI-driven revenue growth.

The market should care because Intel sits at the intersection of three secular trends: AI infrastructure spending, chiplet/advanced packaging adoption, and onshore semiconductor manufacturing. A successful turnaround means Intel not only benefits from AI demand but captures higher margin share by selling more advanced nodes and packaging solutions to hyperscalers and telecom providers.

Data and Recent Performance That Support the Thesis

Valuation and scale: Intel trades with a market cap of $551.9B and enterprise value of $579.84B. Price-to-sales sits at 10.27 and EV/sales at 10.79; EV/EBITDA is 43.85. Those multiples look premium on the surface, but they must be read against the backdrop of a company that can meaningfully expand DCAI revenue and monetize its foundry investments over several years.

Profitability and cash flow: reported earnings per share stood at -$0.63 most recently, and free cash flow is negative $4.446B. Return on assets is -1.55% and return on equity -2.85%. Those numbers reflect the heavy investment phase Intel is in; negative FCF is a short-term reality tied to capex and inventory while the firm builds capacity for AI chips and advanced packaging.

Technicals and market structure: the stock sits at $109.81 with a 52-week high of $142.35 (06/30/2026) and a 52-week low of $18.97 (08/01/2025). Short interest has remained meaningful with the most recent settlement showing roughly 127.8M shares short. Average daily volume is high (two-week and 30-day averages north of 100M), which supports tradeability and liquidity for larger position sizes.

Valuation Framing

Intel’s multiples look elevated relative to the company’s current profitability, but context matters: the market is effectively paying for future DCAI scale and foundry maturation. Market cap $551.9B versus enterprise value $579.84B implies notable net debt or other balance sheet considerations factored in, and EV/EBITDA of 43.85 reflects low current EBITDA that should rise as AI revenue ramps. Price-to-book at ~4.96 shows investors expect far higher returns on Intel’s asset base than today’s ROE of -2.85%.

Put simply, investors are pricing an optimistic execution scenario. Our thesis is that execution is trending in the right direction and catalysts over the next 1-6 months will make that optimism more defensible.

Catalysts

  • Foundry contract announcements or capacity commitments from large cloud customers - proof points that IFS is signing and scaling production.
  • DCAI product ramps and design wins for AI accelerators showing up in bookings and revenue mix improvements.
  • Margin improvement commentary tied to yield and product mix - any guidance that narrows the negative FCF outlook will be a catalyst.
  • Government / supply-chain initiatives such as the Arizona supplier expo on 07/29/2026 that strengthen the domestic manufacturing narrative and could unlock new partnerships.

Trade Plan (Actionable)

We recommend a long trade with clearly defined risk parameters. This is a directional trade sized to reflect a conviction that execution will continue to improve while acknowledging elevated multiples and execution risk.

Entry Stop Target Trade Direction Horizon
$109.81 $98.00 $140.00 Long Mid term (45 trading days) primary; view extends to Long term (180 trading days) for full thesis

Rationale for horizon: the primary price objective to $140 is within a mid-term window (45 trading days). This allows time for a series of catalysts - a product ramp update, foundry announcement, or margin guidance - to be digested by the market. The longer 180-day view is the fundamental investor horizon: that period is when FCF profile and EBITDA should begin to reflect the capex investments.

Key Points to Monitor

  • Monthly/quarterly commentary on DCAI bookings and design wins - incremental data center wins materially change forward revenue expectations.
  • IFS contract timing and production ramp - lead indicators include customer samples, capacity commitments and yield improvements.
  • Margins and FCF trajectory - shrinking negative free cash flow and improving EV/EBITDA trends help justify valuation.
  • Technical support at $98 and $95 levels - a break below the stop would signal the recovery narrative is stalling.

Risks and Counterarguments

  • Execution risk on foundry and process nodes. Intel must deliver yields and timelines comparable to leading competitors. Any meaningful delay will hit margins and push out the timeline to profitability.
  • Valuation is already rich vs current profitability. EV/EBITDA of 43.85 and P/S of 10.27 mean expectations are baked in; if revenue ramps disappoint, downside can be severe.
  • Competitive intensity from TSMC, Samsung and internal rivals for AI accelerators could blunt market share gains in DCAI.
  • Capital intensity and negative free cash flow - the firm reported negative free cash flow of $4.446B. Continued negative FCF or unexpected capex increases would pressure the balance sheet and share price.
  • Macro or cyclical demand weakness for semiconductors could reduce cloud capex and slow the AI server refresh cycle that underpins much of the thesis.

Counterargument: The strongest counterargument is that the market has already priced Intel’s recovery - the elevated multiples reflect a best-case outcome. If Intel fails to convert design wins into steady volume or if yield improvements take longer than anticipated, the company will look like an expensive capital spender rather than a re-emerging profitable foundry and AI vendor. That outcome would favor a neutral or short stance.

What Would Change Our Mind

We would downgrade the trade if any of the following occurs: (1) DCAI bookings show a sequential decline or material customer cancellations; (2) IFS public customer wins fail to progress to production samples within stated timelines; (3) company guidance materially reduces expected margin expansion or extends negative free cash flow beyond the current planning horizon; or (4) the stock decisively breaks below $98 on high volume, suggesting institutional de-risking.

Conclusion

Intel’s turnaround is no longer only a story of future possibility - it is increasingly a story of execution. The company still carries investor risk: high multiples, negative FCF and fierce competition. But with DCAI momentum, visible foundry progress and a string of near-term catalysts, the risk/reward now favors a tactical long. Enter at $109.81, use a hard stop at $98.00, and target $140.00 in the mid-term (45 trading days), keeping the 180-day horizon in the back pocket for the fuller fundamental recovery to prove out.

Key Dates to Watch

  • 07/29/2026 - Arizona Supplier Matchmaking Expo (Intel participation)
  • Next quarterly earnings / investor day - look for DCAI mix commentary and FCF guidance

Trade idea summary: Buy Intel at $109.81, stop $98.00, target $140.00. Mid-term catalyst-driven upside with longer-term fundamental optionality.

Risks

  • Foundry/process node execution delays that hurt yields, margins and customer confidence.
  • Valuation contraction if revenue ramps in DCAI and IFS disappoint relative to high market expectations.
  • Prolonged negative free cash flow and higher-than-expected capex could weaken the balance sheet and valuation.
  • Intense competition from TSMC and Samsung in advanced nodes and AI accelerators could limit market share gains.

More from Trade Ideas

CoreWeave Pullback Overstates the Risk from Meta - Buy the Dip for a 180-Day Trade Jul 11, 2026 Buy the Recovery: Palantir as an Elite, High-Conviction Long on AI Software Repricing Jul 11, 2026 InterDigital: Licensing Momentum and Cash Flow Make a Compelling Long Trade Jul 11, 2026 Pfizer Is Quietly Resetting: A Dividend-Fueled Recovery Trade Jul 11, 2026 Havertys: Targeting Affluent Buyers — A Tactical Long With Yield and Upside Jul 11, 2026